1/29/2013

Biosensors International has earned CE mark approval to market its BioFreedom system, a polymer-free stent that delivers the anti-restenosis drug Biolimus A9. The Singapore-based company aims for a limited launch of the device this year and a full market release next year.

Related Summaries